Cost of diabetes medication
Pro Research Analysisby 
Searched over 200M research papers
Rising Costs of Diabetes Medication in the United States
The cost of diabetes medication in the United States has increased dramatically over the past two decades. National spending on glucose-lowering drugs rose by 240% from $16.9 billion to $57.6 billion per year between 2005–2007 and 2015–2017. During this period, the average annual cost per user increased by 147%, from $1,106 to $2,727, even as the number of people using these medications grew by 38% . From 2014 to 2019, the average monthly cost per user for antidiabetic medications increased by 47.5%, with newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists contributing significantly to these rising costs .
Factors Driving High Diabetes Medication Prices
Several factors contribute to the high cost of diabetes medications, especially insulin. These include the shift from older, less expensive animal-based insulins to newer, genetically engineered human insulins and analogs, frequent price increases, prescribing practices favoring newer drugs, limited ability for payers to negotiate prices, and a lack of transparency in rebate and discount negotiations . Brand-name diabetes therapies are especially expensive, with average cash prices per unit much higher than for insulins or generic drugs. Chain pharmacies tend to offer lower and more consistent prices compared to independent pharmacies, but significant price variation still exists, especially for non-insulin generics .
Comparison to Cost-Based Prices
Economic evaluations suggest that diabetes medications could be manufactured and sold for much less than current market prices. For example, SGLT2 inhibitors could be produced for $1.30 to $3.45 per month, and some insulin regimens could cost as little as $61 to $111 per year, far below what patients currently pay . This indicates that there is a large gap between production costs and retail prices, limiting access for many patients.
Global and Regional Variations in Diabetes Medication Costs
In economically developed countries, the mean annual cost of diabetes medicines per person ranges from $140 to $2,990, with medicines and hospitalization being the largest contributors to direct costs . In low- and middle-income countries, annual medication costs vary widely, from $15 to over $500 per patient, with insulin costs showing particularly large variation . These differences highlight the global challenge of making diabetes treatment affordable.
Impact of High Out-of-Pocket Costs on Patients
High out-of-pocket costs for diabetes medications are a significant barrier to adherence. When patients face monthly out-of-pocket costs above $51–$75, their medication adherence drops sharply, leading to worse health outcomes . The financial burden is especially severe for uninsured individuals and those with high-deductible insurance plans, who are least able to afford these medications .
Cost of Pharmacy Services in Diabetes Care
Pharmaceutical costs make up the vast majority of pharmacy service expenses for diabetes patients—about 98%—with the average annual pharmacy cost per patient being around $1,246 . This underscores the importance of medication costs in the overall financial burden of diabetes care.
Strategies for Reducing Diabetes Medication Costs
To address the high cost of diabetes medications, experts suggest policy interventions such as stricter patent exclusivity requirements, greater transparency in pricing, more opportunities for price negotiation, and outcomes-based pricing models . Shifting prescribing practices toward lower-cost drugs and integrating pharmacist-led management programs may also help control costs and improve outcomes 310.
Conclusion
The cost of diabetes medication has risen sharply, driven by newer drug classes, market practices, and limited price controls. These high costs create barriers to access and adherence, especially for vulnerable populations. There is strong evidence that diabetes medications could be made available at much lower prices, and policy changes are needed to ensure broader, more affordable access to these essential treatments.
Sources and full results
Most relevant research papers on this topic